MDMA Therapy for PTSD: Inching Closer to—or Farther From—Approval?
The Senior Care Pharmacist July 31, 2024 Leigh Davitian 1 citation
MDMA-assisted psychotherapy shows exceptional efficacy for PTSD and medication-resistant depression, with 40-60% of people with PTSD not responding to standard antidepressants. The FDA designated it a breakthrough therapy in 2017, Phase 3 trials are underway, and expanded access was granted in the US and Israel in 2020. Approval could come as early as 2024, offering a potential treatment for a condition affecting almost 3.5% of US adults.